Substitution of the γ-chain Asn308 disturbs the D:D interface affecting fibrin polymerization, fibrinopeptide B release, and FXIIIa-catalyzed cross-linking

Blood

Volumn 103, Issue 11, 2004, Pages 4157-4163

  Okumura, Nobuo ^a   Gorkun, Oleg V ^b   Terasawa, Fumiko ^b   Lord, Susan T ^b  

^a SHINSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; BLOOD CLOTTING FACTOR 13A; CALCIUM; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE B; ISOLEUCINE; LYSINE; POLYMER; THROMBIN;

AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CROSS LINKING; CRYSTALLOGRAPHY; ENZYME MECHANISM; FIBRIN POLYMERIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN VARIANT; TURBIDITY;

EID: 2542445312     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4296     Document Type: Article

References (51)

1. Blomback B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res. 1996;83:1-75.
2. Doolittle RF. Fibrinogen and fibrin. Ann Rev Biochem. 1984;53:195-229.
3. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem. 1993;268:13577-13585.
4. Pratt KP, Cote HCF, Chung DW, Stenkamp RE, Davie EW. The primary fibrin polymerization pocket: three-dimensional structure of a 30 kDa C-terminal γ chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci U S A. 1997;94:7176-7181.
5. Everse SJ, Spraggon G, Veerapandian L, Riley M, Doolittle RF. Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry. 1998;37:8637-8642.
6. Kostelansky MS, Betts L, Gorkun OV, Lord ST. 2.8 Å crystal structures of recombinant fibrinogen fragment D with and without two peptide ligands: GHRP binding to the "b" site disrupts its nearby calcium-binding site. Biochemistry. 2002;41:12124-12132.
7. Boyer MH, Shainoff JR, Ratnoff OD. Acceleration of fibrin polymerization by calcium ions. Blood. 1972;39:382-387.
8. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature. 1978;275:501-505.
9. Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem. 1979;254:11272-11281.
10. Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A. 1980;77:1374-1378.
11. Spraggon G, Everse S, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997;389:455-462.
12. Matsuda M, Baba M, Morimoto K, Nakamikawa C. 'Fibrinogen Tokyo II' an abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest. 1983;72:1034-1041.
13. Mosesson M, Siebenlist K, DiOrio J, Matsuda M, Hainfeld JF, Wall JS. The role of fibrinogen D-domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ275 Arg → Cys). J Clin Invest. 1995;96:1053-1058.
14. Folk JE, Finlayson JS. The ε-(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Prot Chem. 1977;31:1-133.
15. Cote HCF, Pratt KP, Davie EW, Chung DW. The polymerization pocket "a" within the carboxyterminal region of the γ chain of human fibrinogen is adjacent to but independent from the calcium binding site. J Biol Chem. 1997;272:23792-23798.
16. Everse SJ, Spraggon G, Veerapandian L, Doolittle RF. Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Proamide. Biochemistry. 1999;38:2941-2946.
17. Doolittle RF. X-ray crystallographic studies of fibrinogen and fibrin. J Thromb Haemost. 2003;1:1559-1565.
18. Henschen A, Kehl M, Southan C. Genetically abnormal fibrinogens-strategies for structure elucidation, including fibrinopeptide analysis. Curr Probl Clin Biochem. 1984;14:273-320.
19. Cote HCF, Lord ST, Pratt KP. γ-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the γ chain of human fibrinogen. Blood. 1998;92:2195-2212.
20. Matsuda M, Sugo T, Yoshida N, et al. Structure and function of fibrinogen: insights from dysfibrinogens. Thromb Haemost. 1999;82:283-290.
21. Everse SJ, Spraggon G, Doolittle, RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost. 1998;80:1-9.
22. Bantia S, Bell WR, Dang CV. Polymerization defect of fibrinogen Baltimore III due to a γAsn308 → lle mutation. Blood. 1990;75:1659-1663.
23. Okumura N, Furihata K, Terasawa F, Ishikawa S, Ueno I, Katsuyama T. Fibrinogen Matsumoto II: γ308 Asn → Lys (AAT → AAG) mutation associated with bleeding tendency. Br J Haematol. 1996;94:526-528.
24. Yoshida N, Terukina S, Okuma M, Moroi M, Aoki N, Matsuda M. Characterization of an apparently lower molecular weight γ-chain variant in fibrinogen Kyoto I. The replacement of γ-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site. J Biol Chem. 1988;263:13848-13856.
25. 308 → Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coag Fibrinolysis. 1993;4:679-687.
26. Hogan KA, Lord ST, Okumura N, et al. A functional assay suggests that heterodimers exist in two C-terminal γ-chain dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV. Thromb Haemost. 2000;83:592-597.
27. Okumura N, Terasawa F, Fujita K, Fujihara N, Tozuka M, Koh C-S. Evidence that heterodimers exist in the fibrinogen Matsumoto II (γ308N → K) proband and participate in fibrin fiber formation. Thromb Res. 2002;107:157-162.
28. Lord ST, Gorkun OV. Insight from studies with recombinant fibrinogens. Ann N Y Acad Sci. 2001;936:101-116.
29. Okumura N, Furihata K, Terasawa F. Nakagoshi R, Ueno I, Katsuyama T. Fibrinogen Matsumoto I: A γ364 Asp → His (GAT → CAT) substitution associated with defective fibrin polymerization. Thromb Haemost. 1996;75:887-891.
30. Gorkun OV, Veklich YI, Weisel JW, Lord ST. The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood. 1997;89:4407-4414.
31. Okumura N, Terasawa F, Fujita K, Tozuka M, Ota H, Katsuyama T. Difference in electrophoretic mobility and plasmic digestion profile between four recombinant fibrinogens, γ308K, γ308I, γ308A, and wild type (γ308N). Electrophoresis. 2000;21:2309-2315.
32. Mihalyi E. Physicochemical studies of bovine fibrinogen, IV: ultraviolet absorption and its relation to the structure of the molecule. Biochemistry. 1968;7:208-223.
33. Furlan M, Rupp C, Beck EA. Inhibition of fibrin polymerization by fragment D is affected by calcium, Gly-Pro-Arg and Gly-His-Arg. Biochim Biophys Acta. 1983;742:25-32.
34. Ng AS, Lewis SD, Shafer JA. Quantifying thrombin-catalyzed release of fibrinopeptides from fibrinogen using high-performance liquid chromatography. Methods Enzymol. 1993;222:341-358.
35. Lord ST, Strickland E, Jayjock E. Strategy for recombinant multichain protein synthesis: fibrinogen Bβ-chain variants as thrombin substrates. Biochemistry. 1996;35:2342-2348.
36. Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M. Fibrinogen Kyoto III: a congenital dysfibrinogen with a γ aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood. 1989;74:2681-2687.
37. Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H, Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the γ-chain that impairs the polymerization of fibrin monomer. J Biochem (Tokyo). 1989;105:10-14.
38. Yoshida N, Hirata H, Imaoka S, Matsuda M, Yamazumi K, Asakura S. Effect of calcium on the mobility of γ-chain from fibrinogen Osaka V on sodium dodecyl sulfate-polyacrytamide gel electrophoresis. Thromb Res. 1994;73:79-82.
39. Hogan KA, Gorkun OV, Lounes KC, et al. Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the γ chain of fibrinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem. 2000;275:17778-17785.
40. Koopman J, Haverkate F, Briet E, Lord ST. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem. 1991;266:13456-13461.
41. Mullin JL, Brennan SO, Ganly PS, George PM. Fibrinogen Hillsborough: a novel γGly309Asp dysfibrinogen with impaired clotting. Blood. 2002;99:3597-3601.
42. Nossel HL, Hurlet-Jensen A, Liu CY, Koehn JA, Canfield RE. Fibrinopeptide release from fibrinogen. Ann N Y Acad Sci. 1983;408:269-278.
43. Lewis SD, Shields PP, Shafer JA. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. J Biol Chem. 1985;260:10192-10199.
44. Ruf W, Bender A, Lane DA, Preissner KT, Selmayr E, Muller-Berghaus G. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization. Biochim Biophy Acta. 1988;965:169-175.
45. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII, I: structure, distribution, activation, and function. Crit Rev Clin Lab Sci. 1996;33:357-421.
46. Ariëns RA, Lai T-S, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743-754.
47. McKee PA, Mattock P, Hill R. Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci U S A. 1970;66:738-744.
48. Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). J Lab Clin Med. 1975;85:574-597.
49. Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recombinant fibrinogen γy-364Asp → His, the substitution discovered in a heterozygous individual. J Biol Chem. 1997;47:29596-29601
50. Ebert RF, Bell WR. Fibrinogen Baltimore III: congenital dysfibrinogenemia with a shortened γ-subunit. Thromb Res. 1988;51:251-258.
51. Marchi R, Loyau S, Angles-Cano E, Weisel JW. Structure and properties of clots form fibrinogen Bicetre II (γ308Asn → Lys). Increased permeability due to a larger pores, thicker fibers and decreased rigidity. Ann N Y Acad Sci. 2001;936:125-128.